Alterity Therap 
Welcome,         Profile    Billing    Logout  
 2 Products   20 Diseases  2 Products   2 Trials   188 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ATH434 / Alterity Therap
2021-003231-29: A clinical study of ATH434 in patients with multiple system atrophy. Uno studio clinico su ATH434 in pazienti con atrofia multisistemica

Not yet recruiting
2
60
Europe
NA, [ATH434], Tablet
Alterity Therapeutics Limited, Alterity Therapeutics Limited
Multiple System Atrophy (MSA) Atrofia multisistemica (MSA), Atypical parkinsonism with impairment of the autonomic nervous system, gait instability and reduced muscle coordination Parkinsonismo atipico con alterazione del sistema nervoso autonomo, instabilità della deambulazione e riduzione della coordinazione muscolare, Diseases [C] - Nervous System Diseases [C10]
 
 
ATH434-201, NCT05109091 / 2021-003231-29: Study of ATH434 in Participants with Multiple System Atrophy

Completed
2
77
Europe, US, RoW
ATH434 dose level 1, PBT434, ATH434 dose level 2, Placebo
Alterity Therapeutics, Alterity Therapeutics Limited
Multiple System Atrophy
11/24
11/24
NCT05732415: Biomarker Study of ATH434 in Participants With MSA

Not yet recruiting
2
15
US
ATH434
Alterity Therapeutics
Multiple System Atrophy
10/24
11/24
ATH434-202, NCT05864365: A Biomarker Study of ATH434 in Participants With MSA

Completed
2
10
US
ATH434
Alterity Therapeutics
Multiple System Atrophy
02/25
02/25
ACTRN12620001244998: A Phase 1 Study to Evaluate a Tablet Formulation of PBT434 in Healthy Volunteers

Recruiting
1
42
 
Alterity Therapeutics Limited, Alterity Therapeutics Limited
Multiple System Atrophy, Parkinson's disease
 
 
PBT519 / Alterity Therap
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ATH434 / Alterity Therap
2021-003231-29: A clinical study of ATH434 in patients with multiple system atrophy. Uno studio clinico su ATH434 in pazienti con atrofia multisistemica

Not yet recruiting
2
60
Europe
NA, [ATH434], Tablet
Alterity Therapeutics Limited, Alterity Therapeutics Limited
Multiple System Atrophy (MSA) Atrofia multisistemica (MSA), Atypical parkinsonism with impairment of the autonomic nervous system, gait instability and reduced muscle coordination Parkinsonismo atipico con alterazione del sistema nervoso autonomo, instabilità della deambulazione e riduzione della coordinazione muscolare, Diseases [C] - Nervous System Diseases [C10]
 
 
ATH434-201, NCT05109091 / 2021-003231-29: Study of ATH434 in Participants with Multiple System Atrophy

Completed
2
77
Europe, US, RoW
ATH434 dose level 1, PBT434, ATH434 dose level 2, Placebo
Alterity Therapeutics, Alterity Therapeutics Limited
Multiple System Atrophy
11/24
11/24
NCT05732415: Biomarker Study of ATH434 in Participants With MSA

Not yet recruiting
2
15
US
ATH434
Alterity Therapeutics
Multiple System Atrophy
10/24
11/24
ATH434-202, NCT05864365: A Biomarker Study of ATH434 in Participants With MSA

Completed
2
10
US
ATH434
Alterity Therapeutics
Multiple System Atrophy
02/25
02/25
ACTRN12620001244998: A Phase 1 Study to Evaluate a Tablet Formulation of PBT434 in Healthy Volunteers

Recruiting
1
42
 
Alterity Therapeutics Limited, Alterity Therapeutics Limited
Multiple System Atrophy, Parkinson's disease
 
 
PBT519 / Alterity Therap
No trials found

Download Options